FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $10 billion, in an underwritten, registered public offering, consisting of six tranches:
- $1,000 million of 1.850% senior notes maturing in 2018
- $2,000 million of 2.550% senior notes maturing in 2020
- $1,000 million of 3.250% senior notes maturing in 2022
- $2,750 million of 3.650% senior notes maturing in 2026
- $1,000 million of 4.600% senior notes maturing in 2035
- $2,250 million of 4.750% senior notes maturing in 2046
The senior notes are rated A- by Standard & Poor’s and A3 by Moody’s. The offering is expected to close September 14, 2015, subject to customary closing conditions.
Gilead intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of debt, working capital, payment of dividends and the repurchase of its outstanding common stock pursuant to its authorized share repurchase program.
Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC are acting as lead joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead’s effective shelf registration statement on Form S-3 (File No. 333-194298), copies of which may be obtained from:
Merrill Lynch, Pierce, Fenner & Smith Incorporated
J.P. Morgan Securities LLC
|222 Broadway, 11th Floor||383 Madison Ave.|
|New York, NY 10038||New York, NY 10179|
|Attention: Prospectus Department||Attn: Investment Grade Syndicate Desk|
|(800) 294-1322||(212) 834-4533|
An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at http://www.sec.gov/.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the current market demand for these types of securities and the securities of Gilead, Gilead’s ability to consummate the offering in the currently anticipated timeframe or at all and the negotiations between Gilead and the underwriters. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks that could impact the offering are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, as filed with the U.S. Securities and Exchange Commission, and may be updated by the risk factors set forth in any subsequent filing by Gilead with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.